Bliss Gvs Pharma Ltd. (BSE: 506197) is a Mumbai, Maharashtra-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹7,005 Cr, it ranks #713 by market cap among the 6,137 Indian listed companies on FinBizNet, and #3 of 9 in Non-Prescription Drugs. At ₹623.35 (as of 25 Oct 2026), the share price is 15.8% below its 52-week high of ₹739.90 and 387.4% above its 52-week low of ₹127.90. The share price is up 308.7% over one year and up 34.2% over three months.
| Current Price | ₹623.35 |
|---|---|
| Market Cap | ₹7,005 Cr |
| BSE Code | 506197 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 52.5 |
| Return on Equity | 11.60% |
| Return on Assets | 5.87% |
| 52-Week Range | ₹127.90 – ₹739.90 |
| 1-Year Price Change | +308.7% |
| 3-Month Price Change | +34.2% |
| Beta (1Y) | 0.89 |
| Dividend Yield | 0.32% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.blissgvs.com |
| Revenue | ₹286 Cr |
|---|---|
| Net Profit | ₹51 Cr |
| Net Margin | 18.0% |
| EPS (Basic) | ₹4.73 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes. In addition, it offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials
1. Pharmaceutical and Healthcare-This segment develops, manufactures, and markets pharmaceutical formulations. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. 2. Segment Adjustment-0 3. Health Care-This segment offers health care products. 4. Corporate-0
1. Pharmaceutical and Healthcare-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹43,456 Cr | 40.8 | 48.91% | ₹938 Cr | -11.7% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹15,518 Cr | 23 | 12.36% | ₹2,150 Cr | -18.6% |
| Bliss Gvs Pharma Ltd. | ₹7,005 Cr | 52.5 | 11.60% | ₹286 Cr | +308.7% |
| Zota Health Care Ltd | ₹4,881 Cr | -60.3 | -16.05% | ₹174 Cr | -17.5% |
| Amrutanjan Health Care Ltd. | ₹1,482 Cr | 25.6 | 16.62% | ₹103 Cr | -30.3% |
| Jenburkt Pharmaceuticals Ltd. | ₹404 Cr | 11.7 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹210 Cr | 12.3 | — | — | — |
| Vista Pharmaceuticals Ltd. | ₹39 Cr | -7.9 | -10.82% | — | -37.7% |
| Welcure Drugs & Pharmaceuticals | ₹25 Cr | -5 | -5.50% | — | -75.6% |
Listed by market capitalisation. Ratios are shown for context only.
Bliss Gvs Pharma Ltd. is trading at ₹623.35, with a market capitalisation of ₹7,005 Cr.
Bliss Gvs Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Bliss Gvs Pharma Ltd. has a P/E of 52.5 and a return on equity of 11.60%.
Bliss Gvs Pharma Ltd. is listed on the BSE under the scrip code 506197.
Bliss Gvs Pharma Ltd.'s share price is up 308.7% over one year and up 34.2% over three months. Its 52-week range is ₹127.90 to ₹739.90.
In Q1 FY27, Bliss Gvs Pharma Ltd. reported revenue of ₹286 Cr and net profit of ₹51 Cr, with basic EPS of ₹4.73 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.